Skip to content

Opioid Free Anesthesia on the Quality of Early Recovery

The Effect of Opioid-free Anesthesia Protocol on the Early Quality of Recovery After Thyroidectomy (TOFA Trial): Study Protocol for a Prospective, Monocentric, Randomized, Single-blinded Trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05577962
Acronym
opioid-free
Enrollment
160
Registered
2022-10-13
Start date
2024-08-01
Completion date
2026-12-30
Last updated
2026-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid-free Anesthesia

Keywords

thyroidectomy, the early quality of recovery

Brief summary

To analyze and compare the effect of OFA scheme and traditional balanced anesthesia scheme on QoR15 after thyroidectomy, and further clarify the safety and rationality of OFA scheme in perioperative application of thyroid surgery.

Detailed description

OFA scheme (group T) was given dexamethasone 8mg for anti-inflammatory and antiemetic before operation, flurbiprofen axetil 50mg for preemptive analgesia, and dexmedetomidine was infused under ECG monitoring at an initial rate of 0.5 μ G/kg (more than 10min), then changed to 0.2ug/kg/h, and stopped infusion 20 minutes before operation closure. Before induction, lidocaine (1mg/kg), esketamine (0.5mg/kg), propofol (1-2mg/kg) and rocuronium (0.6mg/kg) were infused slowly, and endotracheal intubation was carried out when the anesthetic was fully effective and the BIS value was about 40. After successful intubation.During the operation, continuous propofol (BIS-guided) plus dexmedetomidine 0.2 μg/kg/h (stopped 20 min before skin closure) plus lidocaine 1 mg/kg/h was used to maintain the depth of anesthesia; The routine anesthesia group (Group C) was induced to give sufentanil 0.3-0.5ug/kg, propofol 1-2mg/kg, rocuronium 0.6mg/kg slowly, and then intubated when the anesthetic was fully effective and the BIS value was about 40. Remifentanil was continuously pumped 0.1-0.2ug/kg during operation min. Total intravenous propofol (BIS guided) plus a continuous remifentanil infusion at 0.1-0.2 μg/kg/min was used to maintain the depth of anesthesia.

Interventions

DRUGOFA group (group T)

OFA scheme (group T) was given dexamethasone 8mg for anti-inflammatory and antiemetic before operation, flurbiprofen axetil 50mg for preemptive analgesia, and dexmedetomidine was infused under ECG monitoring at an initial rate of 0.5 μ G/kg (more than 10min), then changed to 0.2ug/kg/h, and stopped infusion 20 minutes before operation closure. Before induction, lidocaine (1mg/kg), esketamine (0.5mg/kg), propofol (1-2mg/kg) and rocuronium (0.6mg/kg) were infused slowly, and endotracheal intubation was carried out when the anesthetic was fully effective and the BIS value was about 40. After successful intubation.During the operation, continuous propofol (BIS-guided) plus dexmedetomidine 0.2 μg/kg/h (stopped 20 min before skin closure) plus lidocaine 1 mg/kg/h was used to maintain the depth of anesthesia;

Sponsors

Beijing Friendship Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients undergoing elective thyroidectomy under general anesthesia * \>18 year old * The informed consent form has been signed * American Society of Anesthesiologists (ASA) anesthesia grade I - II

Exclusion criteria

* Long term use of opioids * Long term use of NSAIDs * Have a history of psychosis, epilepsy, preoperative anxiety, depression, and emotional management disorders * Patients with increased gastric contents reflux and respiratory tract aspiration * Operation time\>3h * Severe liver and kidney insufficiency, cardiac insufficiency, bradycardia with 2 ° II or 3° atrioventricular block * Those who are allergic to or have contraindications to drugs that may be used in the test * Those who cannot cooperate with researchers

Design outcomes

Primary

MeasureTime frameDescription
The QoR-15 scoreHour 24 after surgeryThe quality of recovery-15 score,The QoR was classified as excellent (QoR-15 \> 135), good (122 ≤ QoR-15 ≤ 135), moderate (90 ≤ QoR-15 ≤ 121) or poor (QoR-15 \< 90).

Secondary

MeasureTime frameDescription
Postoperative VAS scoreHour 24,Hour 48,Hour 72 after surgeryPostoperative Visual Analog Scale score, For measurement of the magnitude of pain, the most used scale is "no pain" (corresponding to the scale of 0) and "pain too intense to be tolerated" (corresponding to the scale of 100)
Postoperative complication rateHour 24,Hour 48,Hour 72 after surgeryPostoperative complication rate
Opioid consumptionHour 24,Hour 48,Hour 72 after surgerymorphine or equivalent daily consumption after surgery if necesssary
Anesthesia related adverse eventsHour 24,Hour 48,Hour 72 after surgeryAnesthesia related adverse events
Postoperative fatigue, ICFS scores after surgeryHour 24,Hour 48,Hour 72 after surgeryIdentity-Consequence Fatigue Scale (ICFS) in patients was used to assess the intensity of fatigue.A questionnaire was developed using the 48 items that remained following the content analysis. All items were rated on six-point adjectival scales with anchors from "not at all" to "all of the time" or "not at all" to "more often than usual."
Postoperative mental stateHour 24,Hour 48,Hour 72 after surgeryPostoperative Mini-Mental State Examination (MMSE) scores.MMSE \<27 was taken to indicate cognitive impairment.
Incidence of chronic pain and quality of life3 months after surgeryIncidence of chronic pain and quality of life
the QoR-15 score 48,72 hours after surgery48,72 hours after sugerythe QoR-15 score 48,72 hours after surgery

Countries

China

Contacts

CONTACTHaijun Hou
lumen208@foxmail.com+8618612568228
CONTACTlu liu
emmaliulu@163.com+8618618418228
PRINCIPAL_INVESTIGATORHaijun Hou

Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 6, 2026